skip to Main Content

Cancer Services

Gastrointestinal Cancer

Please see below all current gastrointestinal cancer clinical trials of the Central Coast Cancer Centre.

Name: PREDICT 5FU

A Study to Describe the Feasibility of Therapeutic Drug Monitoring of 5FU in Cancer Treatment
Principal Investigator: Dr Malmaruha Arasaratnam
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Gastrointestinal Cancer
External page link More information about Predict 5FU study

Name: INTEGRATE II

A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

Principal Investigator: Dr Matthew Wong
Study Coordinator: Richard Clayton
Status: Recruiting
Condition: Gastrointestinal Cancer
External page link More information about INTEGRATE II

Name: ASCOLT

ASPIRIN FOR DUKES C AND HIGH-RISK DUKES B COLORECTAL CANCERS
An International, Multi‐centre, Double-Blind, Randomised Placebo-Controlled Phase III Trial

Protocol Number: AG0213CR
Principal Investigator: Dr Matthew Wong
Study Coordinator: Richard Clayton
Status: Closed
Condition: Gastrointestinal/Colorectal Cancer
External page link More information about ASCOLT

Name: DYNAMIC III COLON

DYNAMIC III: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer. A Multicentre Phase II/III Randomised Controlled Study.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Colon Cancer
External page link More information about DYNAMIC III

Name: DYNAMIC Rectal

A multicentre randomised study for circulating tumour DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Closed
Condition: Rectal Cancer
External page link More information about DYNAMIC Rectal

Name: NABNEC

A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Gastric Cancer
External page link More information about NABNEC

Name: Protocol 8951-CL-5201

A phase 2, open-label, randomized study to assess the antitumor activity and safety of Zolbetuximab (IMAB362) in combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as first line treatment in subjects with Claudin 18.2 (CLDN 18.2) positive, metastatic pancreatic adenocarcinoma.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Pancreatic Cancer
External page link More information about Protocol 8951-CL-5201

Name: SGNLV-005

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for unresectable locally advanced metastatic solid tumours.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Gastrointestinal Cancer
External page link More information about SGNLV-005

More information

For more information about medical oncology clinical trials, please contact the Nurse Unit Manager on 02 4320 9890 or see:

Internal page Research and Clinical Trials

Back To Top